{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "C",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is mutated in a significant number of Parkinson’s disease patients, and over 40 missense mutations have been reported that are scattered throughout LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as mutations in LRRK2 leading to Parkinson’s disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study demonstrates that 14-3-3 binding is mediated by phosphorylation of LRRK2 at two conserved residues (Ser910 and Ser935) and investigates how mutations affect this binding.",
          "judgment": "Yes",
          "reasoning": "The assay used effectively models the disease pathogenesis/mechanism by focusing on the interaction between LRRK2 and 14-3-3 proteins, which is central to LRRK2 function and Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper includes immunoprecipitation assays, phosphorylation site identification by MS, and cellular localization studies.",
          "judgment": "Yes",
          "reasoning": "The specific assays used are valid and have been appropriately controlled, as they include both wild-type and mutant forms of LRRK2, and use of appropriate techniques to assess phosphorylation and protein interactions."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study found that the G2019S mutation displayed approximately 3-fold higher specific activity than wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The functional evidence from the assay directly applies to the G2019S variant, showing a significant change in kinase activity, which is a key functional outcome related to Parkinson’s disease."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2019S variant in LRRK2 shows a very strong pathogenic evidence strength due to the significant increase in kinase activity compared to wild-type LRRK2, as demonstrated through robust functional assays in the study."
    }
  ]
}